Health-care companies rose as winners and losers emerged in the race to dominate the blockbuster obesity-drug market.

Eli Lilly shares rallied after the maker of Zepbound weight-control drug posted a 43% increase in quarterly revenue, blowing past Wall Street expectations.

Danish rival Novo Nordisk compounded losses from Tuesday, when the maker of Ozempic and Wegovy warned that price competition in the U.S. would crimp sales this year.

Amgen shares rallied after strong sales of the biotech firm's asthma treatment and other products offset disappointment about delays for an obesity drug.

AbbVie shares fell even after the drug maker's earnings and growth outlook topped Wall Street targets.

GE Healthcare rose after the maker of imaging technology and other medical equipment posted quarterly revenue growth.

Boston Scientific shares tumbled after the medical-device maker's first-quarter earnings and sales growth projections lagged Wall Street's expectations.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

February 04, 2026 17:00 ET (22:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.